Cancer, COVID
Conditions
Keywords
COVID-19, SARS-CoV-2, ddPCR, cancer, serology
Brief summary
Evaluation of the ddPCR ability to detect the SARS-CoV-2 in nasopharyngeal samples of symptomatic patients with suspected COVID-19 infection using an IgG serological assay (EUROIMMUN Anti-SARS-Cov2 ELISA Ig) as gold/reference standard (FDA validated commercial serologic test).
Detailed description
The Bio-Rad SARS-CoV-2 ddPCR Test is a reverse transcription (RT) droplet digital polymerase chain reaction (ddPCR) test designed to detect RNA from SARS-CoV-2 in specimens (mainly nasopharyngeal, anterior nasal, oropharyngeal and mid-turbinate swab but also nasopharyngeal wash/aspirate and nasal aspirate specimens) collected from individuals who are suspected of COVID-19 infection. This single assay multiplex test enables a one-well reaction with three sets of the oligonucleotide primers and probes which were reported by CDC. Two were selected from regions of the virus nucleocapsid (N) gene. An additional primer/probe included in the panel is set to detect the human RNase P gene (RP) in control samples and clinical specimens. RNA isolated and purified from swab specimens is added to the mastermix comprised of reverse transcriptase whereby RNA is converted into cDNA and then amplified, using the Bio-Rad One-Step RT-ddPCR Advanced Kit for Probes. Briefly, the sample and mastermix RT-ddPCR mixtures are fractionated into up to 20,000 nanoliter-sized droplets in the form of a water-in-oil emulsion. The 96-well RT-ddPCR ready plate containing droplets is sealed with foil using a plate sealer. The emulsions are then thermocycled to achieve reverse transcription to generate cDNA followed by target amplification plus probe hydrolysis in each droplet. After thermocycling is complete, the 96-well RT-ddPCR ready plate is loaded into the Droplet Reader. The Droplet Reader singulates the droplets and flows them past a two-color fluorescence detector (FAM and HEX) in order to determine which contain target (positive) and which do not (negative) for each of the targets identified with the SARS-CoV-2 ddPCR Test: N1, N2 and RP. The ddPCR system uses the QuantaSoft 1.7 and QuantaSoft Analysis Pro 1.0 for analysis software.
Interventions
DIAGNOSTIC_TESTNasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR
Nasopharyngeal and throat/oropharyngeal swabs analyzed by both RT-PCR and ddPCR
Sponsors
Centre Leon Berard
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
Nasopharyngeal and oropharyngeal samples will be analyzed by the standard RT-qPCR test and the ddPCR assay.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years on the day of signing informed consent. 2. Confirmed diagnosis of any type of solid or hematologic tumor. 3. Ongoing anticancer treatment at the time of inclusion or within the last 3 months prior to inclusion (last treatment administration or last loco regional procedure). 4. Suspicion of COVID-19 infection. Patients must not have underwent diagnostic test and/or chest imaging before inclusion. 5. Covered by a medical/health insurance. 6. Signed and dated IRB/ICE approved informed consent form.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To determine the ddPCR ability to detect the SARS-CoV-2 in nasopharyngeal samples of symptomatic patients with suspected COVID-19 infection | At inclusion | Using IgG serological assay (EUROIMMUN Anti-SARS-Cov2 ELISA Ig) as gold/reference standard (FDA validated commercial serologic test) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To determine the RT-qPCR ability to detect the SARS-CoV-2 in nasopharyngeal samples of symptomatic patients with suspected COVID-19 infection | Third week after inclusion | Using IgG serological assay (EUROIMMUN Anti-SARS-Cov2 ELISA Ig) as gold/reference standard |
| To determine the ddPCR and RT-qPCR abilities to detect the SARS-CoV-2 in oropharyngeal samples of symptomatic patients with suspected COVID-19 infection | Third week after inclusion | Using IgG serological assay (EUROIMMUN Anti-SARS-Cov2 ELISA Ig) as gold/reference standard |
| To determine the ability of a clinical diagnosis based both on patients' symptoms and chest CT-scan to detect the SARS-CoV-2 in symptomatic patients with suspected COVID-19 infection | Third week after inclusion | Using IgG serological assay (EUROIMMUN Anti-SARS-Cov2 ELISA Ig) as gold/reference standard |
| To determine the agreements between nasopharyngeal samples and oropharyngeal samples | At inclusion | Using ddPCR and RT-qPCR assays |
| To assess the 28-day mortality rate | Up to the follow-up end (28 days after inclusion) | Rate calculated from the date of the first diagnostic procedure to the date of death of any cause |
| To determine potential predictive factors of death among patients' characteristics | Up to the follow-up end (28 days after inclusion) | Demographics, type of tumor, type of anticancer, treatment, comorbidities, biological parameters |
| To evaluate the over risk of death of patients COVID+ versus COVID- | Up to the follow-up end (28 days after inclusion) | After adjusting on main clinical characteristics and treatment type |
| To determine the agreements between a clinical diagnosis and ddPCR and RT-qPCR assays | At inclusion | Using ddPCR and RT-qPCR assays |
Other
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the sensibility, specificity and diagnostic accuracy of in-house serologic test for the SARS-CoV-2 detection | At inclusion | Comparison of our in-house test to the commercial serology test from EUROIMMUN used for the study |
Countries
France
Outcome results
None listed